Loading clinical trials...

RECRUITINGNA

Galleri® in the Medicare Population.

REACH Study: Galleri® in the Medicare Population.

NCT05673018•GRAIL, Inc.

Summary

This multi-center comparative prospective cohort study is designed to assess the real world clinical impact, including safety and test performance, of Galleri®, a blood-based multi-cancer early detection (MCED) test. The study will seek enrollment that is representative of the Medicare population.

Eligibility

Age

50 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•For Galleri + UC (Galleri-Tested Arm):
•Participants are eligible to be included in the study only if all of the following criteria apply:
•Aged ≥50 years with Medicare coverage, including Traditional Medicare (Part A \& B or Dual Eligibles) or Medicare Advantage.
•Capable of giving informed consent that is legally effective (consent provided by a legally authorized representative is not permitted in this protocol).
•For UC (Not Galleri-tested Arm):
•Participants are eligible to be included in the study only if all of the following criteria apply:
•Aged ≥ 50 years with Medicare coverage, including Traditional Medicare (Part A \& B or Dual Eligibles) or Medicare Advantage.
•Have had ≥ 1 UC visit

Exclusion Criteria

•For Galleri + UC (Galleri-Tested Arm):
•Evidence of having had a previous MCED test (including but not limited to the Galleri test, e.g. CancerSeek, PanSeer). Participation in a study such as GRAIL's STRIVE study where results were not returned is not an exclusion criterion.
•Undergoing clinical evaluation for suspicion of cancer within 6 months prior to enrollment. Personal history of hematologic malignancy and/or invasive solid tumor (excluding non-metastatic basal cell carcinoma and squamous cell carcinoma of the skin):
•1. Diagnosed ≤3 years before expected enrollment date and/or
•2. Diagnosed \>3 years before expected enrollment date and never treated and/or
•3. Currently undergoing active cancer management (not including adjuvant hormone therapy for breast or prostate cancer).
•Current pregnancy.
•Individuals who are currently inpatients at a participating site.
•Individuals who are not willing or able to comply with the protocol procedures.
•Individuals who are not currently registered patients at a participating center.
+10 more criteria

Locations (47)

Sutter Valley Hospitals Auburn

Auburn, California, United States

Sutter Valley Hospitals Davis

Davis, California, United States

Sutter Valley Hospitals Elk Grove

Elk Grove, California, United States

Long Beach Memorial Orange Coast

Fountain Valley, California, United States

Long Beach Memorial Saddleback

Laguna Hills, California, United States

Long Beach Memorial Atlantic

Long Beach, California, United States

Sutter Valley Hospitals Modesto

Modesto, California, United States

Sutter Valley Hospitals PAMF Sutter

Palo Alto, California, United States

Sutter Valley Hospitals Roseville

Roseville, California, United States

Sutter Valley Hospitals Alhambra

Sacramento, California, United States

Key Dates

Start Date

July 12, 2024

Primary Completion Date

September 1, 2030

Completion Date

September 1, 2030

Last Updated

February 10, 2026

Enrollment

50,000

ESTIMATED participants

Conditions

Cancer

Interventions

Multi-Cancer Early Detection Test (Galleri®)

DEVICE

Contacts

GRAIL Medical Information

CONTACT

833-694-2553 customerservice@grail.com

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device

NCT04235764

Bladder Cancer

View study

RECRUITINGPHASE3

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248

Non-small Cell Lung Cancer

View study

RECRUITINGPHASE2

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 10, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Galleri® in the Medicare Population.

Inclusion Criteria

Exclusion Criteria

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial